NasdaqGS - Nasdaq Real Time Price USD

REGENXBIO Inc. (RGNX)

7.20 -0.21 (-2.83%)
At close: October 30 at 4:00:00 PM EDT
7.20 0.00 (0.00%)
After hours: October 30 at 4:00:16 PM EDT
Trade RGNX on Coinbase
Chart Range Bar
Loading chart for RGNX
  • Previous Close 7.41
  • Open 7.38
  • Bid 5.33 x 200
  • Ask 9.01 x 200
  • Day's Range 7.00 - 7.53
  • 52 Week Range 5.45 - 16.19
  • Volume 1,061,611
  • Avg. Volume 1,357,795
  • Market Cap (intraday) 475.295M
  • Beta (5Y Monthly) 1.13
  • PE Ratio (TTM) --
  • EPS (TTM) -3.78
  • Earnings Date Nov 5, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 24.55
  • Zacks Rating Bullish

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

www.regenxbio.com

371

Full Time Employees

December 31

Fiscal Year Ends

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

RGNX
50.00%
S&P 500 (^GSPC)
10.73%

1-Year Return

RGNX
43.84%
S&P 500 (^GSPC)
11.11%

3-Year Return

RGNX
49.90%
S&P 500 (^GSPC)
81.91%

5-Year Return

RGNX
79.68%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized
 

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 108.02M
Earnings 22.71M
Profit Margin 21.02%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-50M
0
50M
100M
-1000.0%
-500.0%
0.0%
 

Analyst Insights

View More

Analyst Price Targets

12.00
24.55 Average
7.20 Current
50.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Latest Rating

Date 10/5/2026
Analyst Mizuho
Rating Action Initiated
Rating Outperform
Price Action Announces
Price Target 22
 

Statistics

View More

Valuation Measures

Annual
As of 10/30/2026
  • Market Cap

    475.63M

  • Enterprise Value

    439.06M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (current)

    --

  • Price/Sales (ttm)

    2.15

  • Price/Book (mrq)

    5.44

  • Enterprise Value/Revenue

    2.52

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -112.58%

  • Return on Assets (ttm)

    -21.20%

  • Return on Equity (ttm)

    -137.63%

  • Revenue (ttm)

    174.48M

  • Net Income Avi to Common (ttm)

    -196.43M

  • Diluted EPS (ttm)

    -3.78

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    105.52M

  • Total Debt/Equity (mrq)

    349.00%

  • Levered Free Cash Flow (ttm)

    -184.26M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

7.20 Current
 

Dividend Score

0 Low
Sector Avg.
100 High
 

Hiring Score

0 Low
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
Sector Avg.
100 High
 

Research Reports

View More
  • Daily – Vickers Top Buyers & Sellers for 08/28/2026

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

     
  • Lowering target price to $8.00

    REGENXBIO INC has an Investment Rating of HOLD; a target price of $8.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.

     
  • Rating increased to a HOLD

    REGENXBIO INC has an Investment Rating of HOLD; a target price of $9.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.

     
  • Raising target price to $8.00

    REGENXBIO INC has an Investment Rating of SELL; a target price of $8.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.

     

People Also Watch